ArticleAmerican journal of cancer research2025
Proteomic landscape of lung adenocarcinoma precancerous lesions reveals mitochondrial dsRNA-associated immune and stress responses.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung adenocarcinoma (LUAD) develops through a stepwise progression from pre-cancerous lesions, including atypical adenomatous hyperplasia (AAH), adenocarcinoma in situ (AIS), and minimally invasive adenocarcinoma (MIA). Understanding the molecular dynamics underlying these transitions is critical for early detection and therapeutic interventions. A comprehensive proteomic analysis was performed on pre-cancerous and early LUAD samples using label-free quantitative mass spectrometry. Immunohistochemistry (IHC) and double fluorescence staining were applied to validate protein expression and mt-dsRNA localization. Trajectory inference was utilized to model dynamic proteomic changes during lesion progression. Mt-dsRNA levels were significantly elevated in pre-cancerous lesions, peaking in AIS. Double fluorescence staining revealed partial co-localization with the mitochondrial marker TOMM20, suggesting mitochondrial origin. Differential γ-H2AX staining patterns, with nuclear positivity in AAH and cytoplasmic positivity in AIS and MIA, indicated stage-specific dynamics of the DNA damage response. Upregulation of dsRNA sensors, including RIG-I and MDA5, and dsRNA-binding proteins (dsRBPs) such as ADAR1 and HNRNPA2/B1, highlighted a complex regulatory feedback network for both oncogenic and anti-tumorigenic effects. Notably, in dsRNA-IP assay, ASPH was enriched across all stages including LUAD, while TMED9 and HNRNPA2/B1 were specific to pre-cancerous lesions, reflecting their stage-dependent roles in tumor transformation. Finally, Trajectory analysis identified distinct proteomic shifts, with AAH lesions exhibiting high progression scores resembling AIS and MIA, underscoring their malignant potential. This study reveals the multifaceted roles of mt-dsRNA and its associated proteins in pre-cancerous lesions, providing insights into immune activation, stress adaptation, and early carcinogenesis. These findings establish a framework for developing biomarkers and targeted therapies aimed at preventing the transition to invasive LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.